Avalo Therapeutics enters $9M at-the-market equity offering with Oppenheimer

Avalo Therapeutics, Inc.

Sales Agreement with Oppenheimer & Co. for up to $9,032,567 of common stock.
Commission of 3.0% of gross proceeds; ATM offering under Rule 415.
Shares sold under existing S-3 registration statement effective May 2, 2023.
Company may suspend or terminate offering; no obligation to sell shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Avalo Therapeutics, Inc. entered into Sales Agreement with Oppenheimer & Co. Inc. valued at up to $9,032,567 (effective 2023-05-04).

Action: entry
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc.
Value: up to $9,032,567
Effective: 2023-05-04

Exact text from the filing

On May 4, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Oppenheimer, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $9,032,567 (the “Offering”).

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015804

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.